Contact | Sitemap | About Medicines Research Responsibility News Investors Careers 1 2 3 4 HIV / AIDS Liver Diseases Hematology / Oncology Cardiovascular Inflammation / Respiratory Other Therapies HIV / AIDS Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose. Product Info Pipeline Info Gilead establishes $1 million hurricane relief fund Funding will help HIV organizations impacted by Hurricanes Harvey and Irma. Read more. Acquisition of Kite Pharma Gilead Sciences to Acquire Kite Pharma for $11.9 Billion. View materials. News September 27, 2017 Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire About Gilead Senior Management Worldwide Operations Ethics Business Conduct Business Partnerships Corporate History Timeline Research Pipeline Clinical Trials Investigator Sponsored Research Medicines Request Information Consumer Product Safety Authorized Distributors of Record Product Approval Timeline Responsibility U.S. Patient Access Developing World Access Corporate Contributions Policy Perspectives Gilead Foundation News Press Releases Events Media FAQs Fact Sheets Media Inquiries Investors Recent News Corporate Governance Stock Information Financial Information SEC Filings Shareholder Center Annual Reports Email Alerts Investor FAQs Investor Contacts Investor Disclaimer Careers Pipeline Our Values Developing-World-Access Corporate-Contributions U.S. Benefits © 2009-2016 Gilead. All rights reserved. Terms of Use | Privacy Statements Product images shown do not represent actual size.